Published in Oncologist on December 15, 2015
Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. Oncotarget (2017) 0.75
Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact. Oncotarget (2017) 0.75
Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. Eur Urol Focus (2016) 0.75
Multidimensional integrative analysis uncovers driver candidates and biomarkers in penile carcinoma. Sci Rep (2017) 0.75
Current Management Strategy for Penile Cancer and Future Directions. Curr Oncol Rep (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
EAU penile cancer guidelines 2009. Eur Urol (2010) 3.03
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer (2007) 2.48
Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int (2014) 1.55
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol (2010) 1.49
Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology (2013) 1.45
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol (2012) 1.32
CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle (2013) 1.18
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One (2013) 1.12
Risk factors for squamous cell carcinoma of the penis--population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res (2014) 1.05
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res (2013) 1.00
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. Lung Cancer (2013) 0.94
Incidence trends and survival of penile squamous cell carcinoma in the Netherlands. Int J Cancer (2010) 0.87
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. Anticancer Drugs (2012) 0.85
Prevalence of human papillomavirus in penile malignant tumors: viral genotyping and clinical aspects. BMC Urol (2015) 0.84
Human Papilloma Virus: Prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma. Int Braz J Urol (2013) 0.84
Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas. Am J Pathol (2014) 0.82
Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int (2010) 0.82
Genomic profiling of human penile carcinoma predicts worse prognosis and survival. Cancer Prev Res (Phila) (2014) 0.82
New pathologic entities in penile carcinomas: an update of the 2004 world health organization classification. Semin Diagn Pathol (2012) 0.81
Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Hum Pathol (2015) 0.78